Accord BioPharma Announces New Executive Leadership in Commercialization and Marketing

George Esgro Jr., a seasoned pharmaceutical industry veteran with experience at various companies including GSK, Amgen and Roche, joins Accord BioPharma from Ashfield Healthcare, where he served as President of Global Business Development. Prior to Ashfield Healthcare, George worked at Quintiles (now IQVIA) in various business roles, where he provided strategy and project oversight as Vice President, General Manager of Business Operations and Strategic Accounts for North America. Commercial North.

With over 12 years in the pharmaceutical industry, Kayla Williams joined Accord BioPharma from Mylan, where she developed international commercialization strategies for biosimilars in oncology, immunology and endocrinology. Kayla has held various business roles with responsibilities including insights and analytics, launch management, forecasting, strategic planning, and portfolio analysis. His skills span multiple go-to-market verticals, including conducting in-depth product reviews, formulating pricing strategies, coding and reimbursement, US channel strategies, and strategy development across all market segments.

Nuvan Augustin Dassanaike brings over 19 years of marketing and digital transformation experience with global life science organizations including Mylan, GSK, ZT Bio Pharma (GNC) and Abbott. Through leadership in digital marketing, innovation and customer experience, Nuvan has contributed to revenue stream gains and market share gains in therapeutic areas such as oncology, respiratory , CNS and gastroenterology.

In his 30 years of market access experience in companies such as GSK, Amgen and Agios, Paul Purdy led teams for market access and sales. He has launched more than 18 products in therapeutic areas such as oncology, endocrinology, rheumatology, neurology and rare diseases. At Accord BioPharma, Paul will lead a team focused on gaining access across channels of payers, distributors and GPO customers.

“This leadership team is built on trusted professional relationships, shared expertise and a desire to evolve existing treatment options to improve the overall experience for patients, caregivers, healthcare professionals and others involved in the healthcare journey,” Kokino said.

About Accord BioPharma
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, and patient-centered therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patient’s perspective and develop high-quality therapies that impact their life. The founders of Accord BioPharma have devoted their time, passion and resources to focusing on specialized care and treatment, proactively developing better ways of working and delivering improved therapies. For more information, visit

Nuvan Dassanaike
Senior Vice President Strategy and Digital Operations and Marketing
Cell: (412) 553-9955

SOURCEAccord BioPharma

Comments are closed.